BRIEF published on 10/11/2024 at 07:35, 1 year 3 months ago Poxel Releases 2023 Universal Registration Document Corporate Governance Annual Financial Report CSR Report Poxel 2023 Registration Document
PRESS RELEASE published on 10/11/2024 at 07:30, 1 year 3 months ago Annual financial and audit reports / Terms of availability of the annual financial report Poxel announces availability of the 2023 Universal Registration Document including financial and governance reports, now filed with the AMF AMF Biopharmaceutical Company Financial Report Universal Registration Document Poxel
BRIEF published on 10/03/2024 at 18:35, 1 year 3 months ago Poxel announces its financial and strategic results for 2023 Financial Results Biopharmaceutical TWYMEEG® Poxel OrbiMed
BRIEF published on 09/30/2024 at 07:35, 1 year 4 months ago Poxel Secures $50M Non-Dilutive Financing from OrbiMed Non-dilutive Financing TWYMEEG® Poxel Royalty Monetization OrbiMed
PRESS RELEASE published on 09/30/2024 at 07:30, 1 year 4 months ago Inside Information / Other news releases Poxel monetizes TWYMEEG® royalties in a USD 50 million deal with OrbiMed. Proceeds to reduce debt and support rare disease activities. Webinars scheduled for investor updates Webinars Royalties TWYMEEG® Poxel OrbiMed
BRIEF published on 09/09/2024 at 07:35, 1 year 4 months ago POXEL announces a significant increase in its sales in the second quarter of 2024 Sales Treasury Partnerships TWYMEEG® Poxel
BRIEF published on 08/16/2024 at 08:16, 1 year 5 months ago Poxel: Evolution of the Share Capital and the Number of Voting Rights Share Capital Voting Rights Actions AMF Poxel
BRIEF published on 08/07/2024 at 08:05, 1 year 5 months ago Sumitomo Pharma and Poxel Unveil Study Results of TWYMEEG® for Type 2 Diabetes TWYMEEG® Poxel Sumitomo Pharma Type 2 Diabetes Renal Failure
PRESS RELEASE published on 08/07/2024 at 08:00, 1 year 5 months ago Inside Information / Other news releases Sumitomo Pharma and Poxel announce topline results from post-marketing clinical study on TWYMEEG(R) for Type 2 Diabetes treatment in Japan. Safety, tolerability confirmed in renal impairment patients Japan Poxel Sumitomo Pharma Type 2 Diabetes TWYMEEG
Published on 01/30/2026 at 14:00, 58 minutes ago CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 6 hours 23 minutes ago Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 6 hours 58 minutes ago Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 12 hours 43 minutes ago Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 14 hours 58 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/30/2026 at 14:11, 47 minutes ago SBF AG expects stable to positive business development in a challenging environment for 2026
Published on 01/30/2026 at 13:30, 1 hour 28 minutes ago North Peak Expands Wabash Gold Mineralization at Prospect Mountain, Nevada
Published on 01/30/2026 at 12:00, 2 hours 58 minutes ago HSBC UK and Sage simplify tax reporting for small businesses ahead of Making Tax Digital
Published on 01/30/2026 at 11:54, 3 hours 4 minutes ago EQS-Adhoc: YOC AG: PRELIMINARY FIGURES FOR THE 2025 FINANCIAL YEAR
Published on 01/30/2026 at 10:30, 4 hours 28 minutes ago ASTA ENERGY SOLUTIONS AG SUCCESSFULLY COMPLETES IPO
Published on 01/29/2026 at 18:00, 20 hours 58 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 21 hours 13 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 21 hours 13 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
